The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings.
To evaluate whether to "buy or sell," you must look at performance and analyst sentiment as of April 2026. Viatris (VTRS) Analyst Ratings & Price Targets (April 2026) mylan stock buy or sell
Management expects roughly 2% total revenue growth and strong free cash flow exceeding $2.5 billion . The company expects 2026 to be a "pivotal
The company is focusing on higher-margin generic launches and its innovative portfolio, including late-stage assets expected to complete enrollment in 2026. Market Cap: ~$17.25 billion as of April 2026. The company is focusing on higher-margin generic launches
Analysts are concerned about a lack of a clear growth strategy following an EBITDA "trough" expected in 2025 due to manufacturing issues.
The consensus among Wall Street analysts is currently a . While some analysts maintain a "Buy" rating, recent price targets suggest limited immediate upside. Current Stock Price: ~$14.81 (as of April 27, 2026).